Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. Issue 2 (31st March 2021)

• Record Type: Journal Article
• Authors: Ayoub, Houssein H; Chemaitelly, Hiam; Makhoul, Monia; Al Kanaani, Zaina; Al Kuwari, Einas; Butt, Adeel A; Coyle, Peter; Jeremijenko, Andrew; Kaleeckal, Anvar Hassan; Latif, Ali Nizar; Shaik, Riyazuddin Mohammad; Abdul Rahim, Hanan F; Nasrallah, Gheyath K; Yassine, Hadi M; Al Kuwari, Mohamed G; Al Romaihi, Hamad Eid; Al-Thani, Mohamed H; Bertollini, Roberto; Al Khal, Abdullatif; Abu-Raddad, Laith J
• Is Part Of: BMJ innovations. Volume 7:Issue 2(2021)
• Page Start: 327
• Page End: 336
• Publication Date: 2021-03-31
• Subjects: vaccination -- COVID-19 -- public health -- communicable diseases; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjinnov-2021-000677
• Languages: English
• ISSNs: 2055-8074

Abstract

Abstract : Background: Vaccines against SARS-CoV-2 have been developed, but their availability falls far short of global needs. This study aimed to investigate the impact of prioritising available doses on the basis of recipient antibody status, that is by exposure status, using Qatar as an example. Methods: Vaccination impact (defined as the reduction in infection incidence and the number of vaccinations needed to avert one infection or one adverse disease outcome) was assessed under different scale-up scenarios using a deterministic meta-population mathematical model describing SARS-CoV-2 transmission and disease progression in the presence of vaccination. Results: For a vaccine that protects against infection with an efficacy of 95%, half as many vaccinations were needed to avert one infection, disease outcome or death by prioritising antibody-negative individuals for vaccination. Prioritisation by antibody status reduced incidence at a faster rate and led to faster elimination of infection and return to normalcy. Further prioritisation by age group amplified the gains of prioritisation by antibody status. Gains from prioritisation by antibody status were largest in settings where the proportion of the population already infected at the commencement of vaccination was 30%–60%. For a vaccine that only protects against disease and not infection, vaccine impact was reduced by half, whether this impact was measured in terms of averted infections or disease outcomes, but the relative gains from using antibody status to prioritise vaccination recipients were similar. Conclusions: Major health and economic gains can be achieved more quickly by prioritizing those who are antibody-negative while doses of the vaccine remain in short supply.